Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)

Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive breast cancer patients with BM. Data were...

Descripción completa

Detalles Bibliográficos
Autores principales: Niikura, Naoki, Yamanaka, Takashi, Nomura, Hironori, Shiraishi, Kazuhiro, Kusama, Hiroki, Yamamoto, Mitsugu, Matsuura, Kazuo, Inoue, Kenichi, Takahara, Sachiko, Kita, Shosuke, Yamaguchi, Miki, Aruga, Tomoyuki, Shibata, Nobuhiro, Shimomura, Akihiko, Ozaki, Yuri, Sakai, Shuji, Kiga, Yoko, Izutani, Tadahiro, Shiosakai, Kazuhito, Tsurutani, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567705/
https://www.ncbi.nlm.nih.gov/pubmed/37821514
http://dx.doi.org/10.1038/s41523-023-00584-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567705/
https://www.ncbi.nlm.nih.gov/pubmed/37821514
http://dx.doi.org/10.1038/s41523-023-00584-5

Ejemplares similares